Allogene Therapeutics announced that Zachary Roberts, currently executive vice president of R&D and chief medical officer, will succeed David Chang as president and CEO on July 1, and will also join the board. Chang, an Allogene co-founder, will continue to serve on the board after stepping down from the top executive role. Roberts is taking over as the off-the-shelf cell therapy company advances its pipeline and supports ongoing clinical and regulatory milestones, with leadership continuity intended to preserve execution on R&D and medical development priorities. The move also signals the company’s internal bench strength, with Roberts’ dual R&D and CMO responsibilities positioning him as the operational owner of both discovery and clinical strategy. For investors and partners, CEO succession at a clinical-stage cell therapy company can materially affect trial cadence, manufacturing plans, and business-development momentum, particularly around platform investments and potential collaborations.